




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61N 1/37, 1/368		A1	(11) International Publication Number: WO 96/25977 (43) International Publication Date: 29 August 1996 (29.08.96)
(21) International Application Number: PCT/US96/01091		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 26 January 1996 (26.01.96)			
(30) Priority Data: 08/391,883 21 February 1995 (21.02.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue Northeast, Minneapolis, MN 55432 (US).			
(72) Inventors: KIEVAL, Robert, S.; 1445 Oregon Avenue North, Golden Valley, MN 55427 (US). HESS, Michael, F.; 3841 Pleasant Avenue South, Minneapolis, MN 55409 (US).			
(74) Agents: ATLASS, Michael, B. et al.; Medtronic, Inc. MS301, 7000 Central Avenue Northeast, Minneapolis, MN 55432 (US).			

(54) Title: **DUAL CHAMBER PACING SYSTEM AND METHOD WITH CONTINUAL ADJUSTMENT OF THE AV ESCAPE INTERVAL SO AS TO MAINTAIN OPTIMIZED VENTRICULAR PACING FOR TREATING CARDIOMYOPATHY**



(57) Abstract

A dual chamber pacemaker is provided having capability for adjusting the AV escape interval so as to optimize the timing of delivered ventricular pace pulses for therapy of patients with cardiomyopathy. The pacemaker system continually monitors to determine when a delivered pace pulse results in a fusion beat, and periodically adjusts the AV escape interval in accordance with the percentage or rate of incidence of such fusion beats. In one specific embodiment, the pacing system determines the percentage of delivered ventricular pace pulses which are followed by fusion beats over a predetermined number of intervals, and decrements AV escape interval when such percentage is not below a predetermined minimum. The pacing system also periodically increments AV escape interval when the rate of fusion beats is acceptable, thereby providing a closed loop system for maintaining the AV interval at an optimally long value consistent with maximizing full capture by delivered ventricular pace pulses. In another embodiment, the V-V escape interval of a non-tracking mode pacemaker is controlled to optimize pre-excitation of the ventricle.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**DUAL CHAMBER PACING SYSTEM AND METHOD
WITH CONTINUAL ADJUSTMENT OF THE AV ESCAPE INTERVAL
SO AS TO MAINTAIN OPTIMIZED VENTRICULAR PACING
FOR TREATING CARDIOMYOPATHY**

BACKGROUND OF THE INVENTION

This invention relates to cardiac pacing systems and methods generally and, in particular, to dual chamber cardiac pacing systems and methods for delivering ventricular pacing pulses synchronized to atrial signals so as to benefit patients with cardiomyopathy and other forms of congestive heart failure and, in particular, patients with Hypertrophic Obstructive Cardiomyopathy (HOCM).

Hypertrophic Obstructive Cardiomyopathy is characterized by a narrowed left ventricular outflow tract (LVOT), which causes a significant increase in the subaortic pressure gradient. The narrowed LVOT is caused by an increased thickness of the interventricular septum which obstructs blood flow during systole, or at the time of cardiac output.

Symptomatic improvement of patients with HOCM can be obtained in some cases with the use of standard pharmacotherapy. However, drugs in use for this therapy have disadvantages which have been cited in the literature. Likewise, surgical intervention, e.g., septal myectomy or mitral valve replacement, is another optional treatment. However, such surgical treatments carry a significant operative mortality and have not been shown to alter the natural history of the disease. See, "Permanent Pacing As Treatment For Hypertrophic Cardiomyopathy," by Kenneth M. McDonald et al., *American Journal of Cardiology*, Vol. 68, pp. 108-110, July 1991.

The value of dual chamber cardiac pacing and treatment of patients suffering from HOCM has been recognized in the literature. Modern multiple-mode, dual-chamber cardiac pacemakers are designed to maintain AV synchrony for damaged or diseased hearts that are unable to do so on their own. For example, a DDD pacemaker has electrical connections to both the atrium and the ventricle, senses electrical signals in both chambers of the patient's heart, and delivers atrial pacing stimuli in the absence of signals indicative of natural atrial depolarization, and ventricular pacing stimuli in the absence of signals indicative of natural ventricular depolarization. Such a dual chamber pacemaker maintains the AV synchrony of the heart by delivering ventricular pace pulses at a controlled AV interval following each atrial event.

Studies have indicated that patients suffering from HOCM may benefit from a pacing treatment wherein a ventricular pace pulse is delivered in a specific timed relationship to the sensed or paced atrial depolarization. In particular, if the right ventricular apex is paced before spontaneous atrio-ventricular conduction activates the left ventricle, the ventricular and ventricular septal activation patterns are altered. This reduces leftward motion of the Septum, thereby reducing the LVOT obstruction and subaortic pressure gradient.

The literature uniformly acknowledges the potential advantages of synchronized A-V pacing for HOCM patients, stressing the importance of achieving ventricular capture. Causing "complete ventricular capture" is important to obtain the above-described septal movement, while selecting the longest AV delay that results in complete ventricular capture is important in order to maximize the atrial contribution to ventricular filling. See U.S. Application S.N. 08/214,933, filed March 17, 1994, Method and Apparatus For Dual Chamber Cardiac Pacing, assigned to Medtronic, Inc., and the literature articles referenced therein. The delivered pace pulse should provide "pre-excitation," i.e., depolarization of the ventricular apex before the septum. This altered pattern of septal contraction, as well as optimal left ventricular filling, is generally recognized as being important to this mode of pacemaker treatment. Further, it appears to be established that such synchronized AV pacing provides HOCM patients a long term benefit, i.e., the benefit remains even after cessation of pacing, since such AV pacing causes a reduction in the obstruction of the LVOT which persists in sinus rhythm after cessation of pacing.

The literature suggests that the AV escape interval should be set at the longest duration that maintains ventricular capture at different exercise levels. See the above-cited McDonald article. It has been suggested that the AV escape interval which allows for maximal pre-excitation of the ventricle by the pacing pulse can be selected by determining the AV escape interval that produces the widest paced QRS complex duration. See "Impact of Dual Chamber Permanent Pacing in Patients With Obstructive Hypertrophic Cardiomyopathy With Symptoms Refractory to Verapamil and β -Adrenergic Blocker Therapy," by Fananapazir et al., *Circulation*, Vol. 8, No. 6, June 1992, pp. 2149-2161.

In the referenced U.S. application assigned to Medtronic, Inc., the pacemaker periodically checks to determine a value of intrinsic AV conduction time (AVC) and subtracts therefrom a ventricular sense offset interval (VSO) to get the AV escape interval. After a waveform of the ventricular depolarization resulting from complete capture is noted and recorded for comparison, the AV escape interval is set to a lengthened value,

resulting in one or more ventricular sense events. The value of AVC is determined as the time difference between the atrial event and the sensed R-wave. Following this, the pacemaker AV escape interval is reduced further until the pacemaker finds an R wave with a waveform that indicates good capture. The difference between AVC and the capture value of A-V is VSO, and the pacemaker thereafter sets AV = AVC - VSO.

The prior art techniques for synchronous pacing of HOCM patients recognize the necessity to periodically evaluate the AV delay, or AV escape interval. The patient's spontaneous atrio-ventricular conduction time generally will change with heart rate, i.e., from rest to exercise. Moreover, simultaneous drug treatment such as beta blockers may also modify AV conduction time and require renewed evaluation of the AV delay. The importance of periodically making an accurate determination of the optimized AV interval thus takes on significance. If the AV delay is adjusted to a value which is too short, in order to ensure complete ventricular capture, the atrial contribution to ventricular filling is compromised. However, if the AV escape interval is adjusted to too great a value, ventricular capture is compromised, and there may be episodes of no ventricular pacing or the ventricular pace may not contribute the best possible reduction of the LVOT obstruction. Accordingly, it is important in this therapy to be able to continuously or periodically adjust the AV escape interval to optimize it for HOCM therapy.

Accordingly, there is a substantial need for an improved method of treating patients having cardiomyopathy or certain forms of congestive heart failure, and a system for carrying out such treatment. The treatment of this invention embodies pacing the patient's ventricle in a timed relationship to the anticipated depolarization which would otherwise occur due to spontaneous atrio-ventricular conduction. While the preferred embodiment involves synchronized dual chamber pacing and adjustment of the AV escape interval, it is within the broader scope of the invention to deliver ventricular pace pulses that have a controlled timing so as to optimize pre-excitation of the ventricle, whether or not the ventricular pace pulses are synchronized to atrial events. Further, while the preferred embodiment is illustrated in terms of treating HOCM, the system and method of this invention are also applicable to treatment of dilated cardiomyopathy and certain forms of congestive heart failure.

SUMMARY OF THE INVENTION

The pacemaker system and method of this invention are based on the observation that when a ventricular pace pulse is delivered with a timing that results in a fusion or near fusion beat, there is a detectable change in the characteristics of the evoked QRS. In the

practice in this invention, such fusion condition can be detected by discriminating a relative change in duration of the evoked QRS signal, a relative change in QRS amplitude, or a change in the QRS morphology, or a change in T-wave characteristics.

In accordance with a preferred embodiment of this invention, the pacemaker system detects fusion beats and monitors the number of fusion beats which occur over a predetermined time interval or number of pacemaker cycles, and determines whether this percentage is acceptable. The acceptable percentage may be zero, i.e., no fusion beats are acceptable, or it may be a suitable non-zero small percentage. When an unacceptable fusion percentage is determined, the pacemaker automatically adjusts AV delay to a lesser value, i.e., a value which restores continuous capture by delivered synchronous ventricular pace pulses. When the pacemaker operation has proceeded for a predetermined time or cycle interval without any determination of non-acceptable fusion beats, the pacemaker increments AV interval toward the fusion value, so as to continually adapt the value toward the longest possible value consistent with avoiding fusion. In another embodiment, the V-V escape interval of a non-tracking mode pacemaker is controlled to optimize pre-excitation of the ventricle.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective representation of the pacemaker system of this invention showing an implantable pacemaker connected to a patient's heart.

Figure 2 is a block diagram of the pacemaker system of this invention, showing a pacemaker inter-connected with an external programmer and with ECG leads.

Figure 3 is a block diagram of the primary functional components of a pacemaker used in the system and method of this invention.

Figure 4A is a generalized flow diagram illustrating steps taken in synchronous pacing in accordance with this invention, including adjusting AV escape interval for optimizing HOCM therapy; Figure 4B is a flow diagram of a generalized routine used by the pacemaker system of this invention in adjusting the AV escape interval for optimized HOCM therapy pacing.

Figure 5 is a representative data plot of QRS duration as a function of pacemaker AV interval.

Figure 6A is a detailed flow diagram of a routine of the pacemaker system of this invention for adjusting AV escape interval as a function of a determined percentage of detected fusion beats; Figure 6B is a simplified flow diagram showing steps for detecting the occurrence of a fusion beat.

Figure 7 is a simplified flow diagram of a routine of an alternate embodiment of the pacemaker system of this invention for adjusting V-V escape interval for providing pacing therapy in a non-tracking mode.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Figure 1 illustrates the external configuration of a dual chamber pacemaker 6, which is provided with a hermetically sealed enclosure 8, typically fabricated of biocompatible metal such as titanium. Mounted to the top of the enclosure 8 is a connector block assembly 12, which receives electrical connectors located on the proximal ends of leads 14 and 16. Lead 16 is an atrial pacing lead, carrying two electrodes 20 and 21. Electrodes 20 and 21 are used both to sense atrial depolarizations and to deliver atrial pacing pulses. Atrial pacing pulses may be delivered between electrode 20 and electrode 21 or between electrode 21 and the housing 8 of the pacemaker 6. Sensing of atrial depolarizations may occur between electrode 20 and electrode 21 or between either of electrode 20 and 21 and the housing 8 of the pacemaker 6.

Similarly, lead 14 represents a ventricular bipolar pacing lead, carrying two electrodes 28 and 29. As discussed above in conjunction with atrial lead 16, electrodes 28 and 29 are used to sense and pace the ventricle. Ventricular pacing may be accomplished between electrodes 29 and 28 or between electrode 29 and the conductive housing 8 of pacemaker 6. Sensing of ventricular signals, including depolarizations (QRS-waves) and repolarizations (T-waves) may be accomplished between electrodes 29 and 28 or between either of electrodes 29 and 28 and the housing 8 of the pacemaker 6.

As discussed in the present application, the preferred embodiments of the pacemaker 6 operate in a DDD or DDDR pacing mode, wherein pacing pulses are delivered to both atrium and ventricle and wherein atrial and ventricular depolarizations are both effective to inhibit delivery of the next scheduled pacing pulse in the chamber in which they are detected. While the present invention is believed optimally practiced in a pacemaker operating in DDD pacing mode, in some patients there may also be a benefit to operating the device in VDD or DVI mode, which provides ventricular pacing pulses synchronized only to sensed atrial depolarizations or only delivered to atrial pacing pulses, respectively, depending upon the specific underlying heart condition of the patient. However, DDD mode is expected to be the mode most widely used to practice the present invention.

Figure 2 illustrates the pacemaker 6 in block diagram form, coupled to a human heart 10, in conjunction with an external programmer/display apparatus corresponding to

those typically employed to program modern, multi-programmable implantable pacemakers. Within the housing of the pacemaker are located the pacing circuitry 320, which includes circuitry performing all of the basic timing, stimulation and sensing functions of a cardiac pacemaker and a microprocessor circuit 302, which controls the timing intervals provided by the pacing circuitry 320. Pacing circuitry 320 also includes a bidirectional telemetry circuit coupled to an antenna 334, allowing transmission of information from external programmer 4 into the pacemaker 6 to modify its parameters and allowing transmission of information from the pacemaker 6 to the external programmer 4, again generally corresponding to telemetry and programming systems presently existing in commercially marketed multi-programmable implantable pacemakers.

The programmer 4 also includes a corresponding antenna 100 coupled to a telemetry/antenna driver circuit 102 which serves to demodulate telemetry signals received from antenna 334 of the pacemaker, and to apply them in parallel or serial digital format to input output (I/O) unit 108, where they in turn may be applied to a video monitor 112 via graphic interface 110, and/or provided to central processing unit 114 and/or printer 118. Microprocessor 114 controls the operation of the programmer/display apparatus, and is responsive to physician entered commands via keyboard 116, for controlling programming signals sent to the pacemaker, as well as for controlling operation of the video display 112 and printer 118. Also illustrated is an ECG interface 104, coupled to three ECG electrodes 106 which can be placed upon the patient's body. ECG interface 104 provides sensed electrograms to input/output device 108, where they in turn may be provided to the video display 112, the central processing unit 114 or the printer 118. The ECG capability is used for treatment according to the method of this invention for a patient who is available for initial or subsequent programming.

Figure 3 is a block functional diagram of the pacemaker illustrated in Figure 1, as connected to a human heart 10. The circuitry illustrated is all located within the conductive housing or can 8 of the pacemaker, as illustrated in Figure 1, and the bipolar leads 14 and 16 are illustrated schematically as coupled directly to the circuit. However, of course, in the actual device they would be coupled by means of removable electrical connectors inserted in the connector block 12, as illustrated in Figure 1.

The pacemaker is divided generally into a microcomputer circuit 302 and a pacing circuit 320. A pulse generator circuit 340 includes a ventricular pulse generator circuit coupled to the heart 10 by means of electrodes 29 and 28 on lead 14, as well as an atrial pulse generator circuit coupled to the heart 10 by means of atrial electrodes 20 and 21,

located on lead 16. Similarly, pacing circuit 320 includes atrial and ventricular sense amplifiers in sense amplifier circuit 360, coupled to the atrium and ventricle by means of leads 14 and 16 as well. The ventricular sense amplifier provides for separate detection and identification of QRS-wave signals, in a known manner; it may also provide for detection and identification of T-wave signals. The atrial sense amplifier provides for respective identification of P-waves and FFRS signals. The output circuit 340 and sense amplifier circuit 360 may contain pulse generators and sense amplifiers corresponding to any of those presently employed in commercially marketed cardiac pacemakers. Control of timing and other functions within the pacemaker circuit is provided by digital controller/timer circuit 300, which includes a set of timers and associated logic. Digital controller/timer circuit 330 defines the basic pacing interval of the device, which may take the form of an A-A escape interval initiated on atrial sensing or pacing and triggering atrial pacing at the expiration thereof, or may take the form of a V-V escape interval, initiated on ventricular sensing or pacing and triggering ventricular pulse pacing at the expiration thereof. Digital controller/timer circuit 330 similarly defines the A-V escape interval, AV_{esc} , discussed in detail below. The specific values of the intervals defined are controlled by the microcomputer circuit 302 by means of data and control bus 306. Sensed atrial depolarizations and FFRSs are communicated to the digital controller/timer circuit 330 on A event line 352; and ventricular depolarizations (QRS-waves) and repolarizations (T-waves) are communicated to the digital controller/timer circuit 330 on V event line 354. In order to trigger generation of a ventricular pacing pulse, digital controller/timer circuit 330 generates a trigger signal on V trig line 342. Similarly, in order to trigger an atrial pacing pulse, digital controller/timer circuit 330 generates a trigger pulse on a trig line 344.

Digital controller/timer circuit 330 also defines time intervals for controlling operation of the sense amplifiers in sense amplifier circuit 360. Typically, digital controller/timer circuit 330 will define an atrial blanking interval following delivery of an atrial pacing pulse, during which atrial sensing is disabled, as well as ventricular blanking intervals following atrial and ventricular pacing pulse delivery, during which ventricular sensing is disabled. Digital controller/timer circuit 330 will also define an atrial refractory period during which atrial sensing is disabled, this refractory period extending from the beginning of the A-V escape interval following either a sensed or paced atrial depolarization, and extending until a predetermined time following sensing of a ventricular depolarization or delivery of a ventricular pacing pulse. Digital controller/timer circuit 330 similarly defines a ventricular refractory period following ventricular sensing or delivery of

a ventricular pacing pulse, which is typically shorter than the portion of the atrial refractory period following ventricular sensing or pacing. Digital controller/timer circuit 330 also controls sensitivity settings of the sense amplifiers 360 by means of sensitivity control 350. Control 350 is also utilized to generate timing windows for isolation and detection of portions of the received waves, e.g., FFRS signals from the atrial channel and R-wave and T-wave portions respectively from the ventricular channel.

In the embodiment illustrated in Figure 2, the pacemaker is provided with a piezo electric sensor 316 which is intended to monitor patient activity, in order to allow provision of rate responsive pacing, such that the defined pacing rate (A-A escape interval or V-V escape interval) increases with increased demand for oxygenated blood. Sensor 316 generates electrical signals in response to sensed physical activity which are processed by activity circuit 322 and provided to digital controller/timer circuit 330. Activity circuit 332 and associated sensor 316 may correspond to the circuitry disclosed in U.S. Patent No. 5,052,388, issued to Betzold et al., and U.S. Patent No. 4,428,378, issued to Anderson et al. incorporated herein by reference in their entireties. Similarly, the present invention may be practiced in conjunction with alternate types of sensors such as oxygenation sensors, pressure sensors, pH sensors and respiration sensors, all well known for use in providing rate responsive pacing capabilities. Alternately, QT time may be used as the rate indicating parameter, in which case no extra sensor is required. Similarly, the present invention may also be practiced in non-rate responsive pacemakers.

Transmission to and from the external programmer 4 illustrated in Figure 2 is accomplished by means of antenna 334 and associated RF transmitter and receiver 322, which serves both to demodulate received downlink telemetry and to transmit uplink telemetry. Crystal oscillator circuit 338 provides the basic timing clock for the circuit, while battery 318 provides power. Power on reset circuit 336 responds to initial connection of the circuit to the battery for defining an initial operating condition and similarly, resets the operative state of the device in response to detection of a low battery condition. Reference mode circuit 326 generates stable voltage reference and currents for the analog circuits within the pacing circuit 320, while analog to digital converter ADC and multiplexor circuit 328 digitizes analog signals and voltage to provide real time telemetry of cardiac signals from sense amplifiers 360, for uplink transmission via RF transmitter and receiver circuit 332. Voltage reference and bias circuit 326, ADC and multiplexor 328, power on reset circuit 336 and crystal oscillator circuit 338 may correspond to any of those presently used in current marketed implantable cardiac pacemakers.

Microcomputer circuit 302 controls the operational functions of digital controller/timer 330, specifying which timing intervals are employed, and controlling the duration of the various timing intervals, via data and control bus 306. Microcomputer circuit 302 contains a microprocessor 304 and associated system clock 308 and on processor RAM circuits 310 and 312, respectively. In addition, microcomputer circuit 302 includes a separate RAM/ROM chip 314. Microprocessor 304 is interrupt driven, operating in a reduced power consumption mode normally, and awakened in response to defined interrupt events, which may include delivery of atrial and ventricular pacing pulses as well as sensed atrial and ventricular depolarizations. In addition, if the device operates as a rate responsive pacemaker, a timed interrupt, e.g., every cycle or every two seconds, may be provided in order to allow the microprocessor to analyze the sensor data and update the basic rate interval (A-A or V-V) of the device. In addition, in a preferred embodiment of the invention, the microprocessor 304 may also serve to define variable A-V escape intervals and atrial and ventricular refractory periods which may also decrease in duration along with decreases in duration of the basic rate interval. Specifically, the microprocessor is used to carry out the routines illustrated in Figures 4A, 4B, 5A and 5B.

The illustrated circuitry of Figure 3 is merely exemplary, and corresponds to the general functional organization of most microprocessor controlled cardiac pacemakers presently commercially available. It is believed that the present invention is most readily practiced in the context of such a device, and that the present invention can therefore readily be practiced using the basic hardware of existing microprocessor controlled dual chamber pacemakers, as presently available, with the invention implemented primarily by means of modifications to the software stored in the ROM 312 of the microprocessor circuit 302. However, the present invention may also be usefully practiced by means of a full custom integrated circuit, or any combination of hardware and software.

Referring now to Figure 4A, there is shown a generalized flow diagram of steps taken by a pacemaker system in accordance with this invention in performing synchronous pacing, with adjustment of AV_{esc} for optimal HOCM therapy. The steps of this flow diagram are suitably carried out by microcomputer circuit 302. This is a simplified flow diagram setting forth only steps pertinent to controlling AV_{esc} , and does not include many other steps and responses that occur during each cycle of a typical dual chamber pacemaker. The illustrated logic of Figure 4A recognizes that the intrinsic AV conduction time following an atrial pace pulse is greater than following a sensed atrial depolarization, by an amount described as "atrial sense offset", or ASO in referenced U.S. application

08/214.933. The AV_{esc} following an atrial pace is defined as PAV; the AV_{esc} following an atrial sense is defined as SAV; and $PAV = SAV + ASO$.

At block 401, the routine of Fig. 4A is waiting for what is expected to be an atrial event. When an event occurs, the routine goes to block 402 and determines whether there has been timeout of the atrial escape interval, A_{esc} . If yes, this indicates that an atrial pace (AP) should be delivered, and this is done at block 404. Following this, the routine sets AV_{esc} to PAV, and initiates timeout of AV_{esc} . Returning to 402, if there has been no timeout of A_{esc} , the pacemaker proceeds to 408, and determines whether there has been an early ventricular sense (VS). If yes, the routine branches to block 409 and resets the timing appropriately, whereafter it returns to block 401. However, as would normally be the case, if at 408 the event is not a VS, meaning that it has been an atrial sense (AS), the routine proceeds to block 410 and sets AV_{esc} to the current value of SAV. Following this, the routine goes to 412 and initiates timeout of the atrial escape interval (A_{esc}), and timeout of the AV escape interval, AV_{esc} (either SAV or PAV). Then, at 414, the pacer waits for the next event, normally a ventricular event.

At 415, the pacemaker responds to an event by first determining whether the event was a timeout of AV_{esc} . If no, meaning that there was a ventricular sense, the pacemaker proceeds to block 417 and resets PAV and SAV to a shorter value which ensures capture by the next ventricular pace pulse. For example, each of these values can be decremented by 20 or 50 ms, to ensure that succeeding timeouts of AV_{esc} occur early enough for complete capture. It is to be noted, however, that the algorithms discussed below are designed to avoid an occurrence of VS, such that the pacemaker should rarely take this path.

If at 415 there has been a timeout of AV_{esc} , then the pacemaker proceeds to block 418 and delivers a V pace. Then, at block 419, the pacemaker determines whether it is programmed to go into the AV adjust routine. If no, the routine is done and it exists back to 401. If yes, the pacemaker goes to the adjust AV routine at block 420. Here, the pacemaker analyzes collected data, e.g., VP-FFRS time; FFRS duration; or FFRS or QRS amplitude. With this data in hand, the pacemaker system can adjust the values of PAV and SAV, in accordance with a predetermined algorithm for changing AV_{esc} so as to optimize resultant pre-excitation. Following this, the routine returns to block 401 and waits for the next atrial event.

Note that the pacemaker can be programmed for automatically monitoring AV data and adjusting AV_{esc} each pacemaker cycle, or these steps can be taken on some other

periodic or user-programmed basis, within the scope of the invention. For an implanted pacemaker which is set to automatically adjust AV, the pacemaker goes directly to 420. Similarly, for a pacemaker system in accordance with this invention which adapted to be programmed specifically by a physician, the routine exits unless the programming sequence has been activated.

Figure 4B is a simplified flow diagram showing the primary steps of a generalized routine for controlling AV escape interval as a function of determined percentage. At 430, it is determined whether the pacemaker is programmed to go into the test to determine whether AV escape interval should be changed. The programmer may be permanently set to conduct a test repetitively, or may be programmed from an external programmer by a physician. Assuming that the pacemaker is so programmed, at 432 the pacemaker runs a routine to get the percentage fusion. This routine is illustrated in greater detail in connection with Figures 5, 6A and 6B. After this, at block 434, it is determined whether the percentage is less than a predetermined minimum, e.g., less than .5%, 1%, 2%, etc. If yes, meaning that the number of fusion beats is acceptably low, the routine branches to block 440, and determines whether to increment AV escape interval. This decision is preferably made as a function of the detected percentage. For example, if the percentage is 0, the decision is made to increment, and at 442 AV is incremented by a small amount $\Delta 2$, e.g., 5 ms.

Returning to decision block 434, if the percentage is not less than the predetermined minimum, the routine goes to block 436 and determines a decrement amount $\Delta 1$ as a function of the detected percentage. Thus, for example, if the percentage is relatively high, $\Delta 1$ can be set to a relatively higher figure, e.g., in the range of 20-50 ms. If the percentage is lower, $\Delta 1$ may be more suitably set to a figure in the range of 5-10 ms. Then, at 438 AV is decremented by $\Delta 1$, and the routine exits.

Referring now to Figure 5, there is shown a plot of data representative of QRS or FFRS duration (ms) as a function of pacemaker AV interval (ms). As seen in Figure 5, the QRS duration is relatively low at higher AV intervals which are greater than the patient's intrinsic PR conduction time, i.e., where a VS occurs before timeout of AV_{esc} . However, as AV_{esc} is shortened, it comes into a fusion area where QRS increases and peaks; at shorter intervals, where a VP results in full capture, QRS duration is substantially constant at a value higher than the values corresponding to spontaneous QRSs. The knee portion between full capture and failure to capture is termed the fusion area, or range, and the ability to detect duration changes in this area provides the basis for one embodiment of this

invention. As used herein, the term "fusion" embraces the entire range, including the lower portion of the range referred to as "onset of fusion." In the discussions of Figures 6A and 6B below, detection of fusion may be determined by examination of QRS duration to see whether operation is within the fusion range, or any part of it. Alternately, fusion may be determined by comparing other QRS characteristics, such as morphology and amplitude. Additionally, fusion may be determined by detection of changes in the ventricular repolarization, or T-wave, as well as changes in the VP-QRS time, i.e., the time interval between delivery of a ventricular pace pulse and the evoked QRS.

Still referring to Figure 5, it is noted that there is a variation in the degree of fusion within the fusion range. Thus, there is maximal fusion toward the center of the range, and minimal fusion toward the upper and lower limits of the range. It is within the scope of the invention to measure the degree of fusion, and control as a function of the degree of fusion. For example, a beat with no greater than X% fusion can be deemed acceptable, such that the algorithm would allow a maximum of Y% of the beats to have greater than X% fusion.

Referring now to Figure 6A, the routine is initially entered at 640, where the AV interval is set equal to a nominal predetermined value. At 641 three routine variables are set equal to 0, namely PACECOUNT, FUSECOUNT, and DECADECOUNT. Following this, the routine goes to block 642, and waits for an atrial event, either sense or pace. The pacemaker sets AV_{esc} , as illustrated in Figure 4A, and proceeds to block 644 where it waits for a V event, either sense or pace. At 646, if the V event has been a sense, the routine branches to 647 and sets the three routine variables to 0. Thereafter, at 648, the AV interval is decremented by a predetermined value Y, to bring the interval back to a shorter value so as to ensure synchronous pacing with capture. At 649 the pacemaker checks to see if the new value of AV interval is equal to or greater than a programmed value AV_{MIN} and adjusts the value if necessary at 650 before returning to the wait for the next atrial event.

If, at 646, it is determined that there has been a delivered ventricular pace pulse, then at 652 the variable PACECOUNT is incremented by 1. Then, at 653, the pacemaker system waits for an evoked response, and determines whether there has been a fusion beat. As discussed previously, fusion can be determined in a number of different ways. In the preferred embodiment, fusion is determined by detecting a significant decrease in duration of either the QRS waveform from the V sense channel, or the FFRS waveform from the A sense channel. Reference is made to Fig. 6B, and the discussion relating thereto. If fusion is detected, the variable FUSECOUNT is incremented at 654. Then, at 655 the value of

PACECOUNT is compared to a predetermined number, e.g. 10. If PACECOUNT has not reached the predetermined number, the routine returns to 642. However, if it has, the routine goes to 657 and determines the percent of fusion beats in the last n cycles (e.g., 10), and whether this percentage is acceptable. If no, the routine branches to 658, resets the three routine variables to 0, and then at 659 decrements AV by a fixed amount indicated as Z. Z, for example, may be in the range of 20-50 ms, chosen to shorten AV interval so that it is safely short of the value where fusion has been detected.

Returning to 657, if the percent fusion occurrences is acceptable, e.g., there have been no fusion beats or less than the minimum acceptable percentage, the routine goes to 662 and sets PACECOUNT and FUSECOUNT equal to 0. DECADECOUNT is incremented by 1, and then at 664 the DECADECOUNT is compared to a fixed number, illustrated as 6. A DECADECOUNT of 6 is seen to correspond to 60 cycles in this example. If the DECADECOUNT count has not reached 6, the routine returns to 642. However, if it has, this means that pacemaker activity has remained quiescent for a predetermined number of cycles, and the routine reacts by adjusting AV_{esc} so as to search for a fusion value of the AV interval. The routine goes to 666 and increments AV_{esc} by a variable T, suitably 5 ms, which takes it toward the fusion range. DECADECOUNT is set back to 0. Then, at 668 AV is compared to AV_{MAX} , and is set equal to AV_{MAX} at 670 if required. It is seen that in this manner, as long as no unacceptable fusion percentage is detected, the AV interval is periodically incremented toward a fusion value, thereby providing a closed loop control for keeping the value of AV escape interval within a short range. The range of AV_{esc} has a high limit at about the onset of fusion, and is dynamic so as to track with time any changes in the patient's intrinsic conduction interval.

Referring now to Figure 6B, there is shown a simplified flow diagram for determining whether a fusion beat has occurred. At 670, the pacemaker gets the QRS or T-wave, and examines the wave at 672 to obtain a wave characteristic. As discussed above, this characteristic may be duration, as illustrated in Figure 5, or any other signature type characteristic. The data reflecting the characteristic are stored with the identification CHAR1. Then, at 674, the pacemaker compares the characteristic data just obtained (CHAR1) with the characteristic data of the prior signal designated as CHAR2. Based on this comparison, at 676, the pacemaker makes a determination as to whether or not a fusion beat has just occurred. Then, CHAR 2 is set equal to the just obtained CHAR 1 at 678 or 679, for use during the next cycle. The steps of obtaining characteristics at 672 are accomplished by use of standard hardware, preferably also using digital processing

techniques. For determining QRS width, or duration, this signal is processed to determine when it first rises to a predetermined level, and when it falls back below such level. Amplitude is suitably measured by either a simple peak detector or other standard amplitude detection circuitry. For getting the time of VP-QRS, a standard edge detector may be utilized in circuit 330 to sense when the leading edge of the QRS signal has reached the predetermined level, or has increased by a predetermined percentage. These standard circuits may be supplemented or replaced by known digital processing techniques carried out with the aid of microprocessor system 302. Note also that fusion can be determined by comparing the wave characteristic with a standard wave, i.e., a reference characteristic, taken from a full capture wave evoked by a ventricular pace pulse delivered after a short AV_{esc} .

It is to be noted that while the preferred embodiment has been illustrated in terms of determining the percentage of fusion beats that is acceptable, similar arrangements are within the scope of the invention. Thus, the algorithm for determining whether the number of fusion beats is acceptable or non-acceptable may involve any desired degree of complexity. For example, the determination may be made on the basis of total accumulated fusion beats over a predetermined time interval, e.g., on a daily basis. Alternately, the percentage of fusion beats that is acceptable may be adjusted in accordance with monitored patient history, and likewise the adjustment following a determination of an unacceptable fusion rate may be varied as a function of patient history.

While the preferred embodiments of the invention had been described with reference to dual chamber pacemakers, and control of the AV escape interval, the therapy provided by this invention can also be provided by a pacemaker system which is operating in a non-tracking, or asynchronous mode. For example, in dual chamber pacemakers with a "Modeswitching" feature, the pacing mode is automatically changed from an atrial tracking mode (VDD, DDD, DDDR) to a non-tracking mode (DDIR or VVIR) upon detection of an atrial arrhythmia. In these situations, the pacemaker cannot track the atrial signal because the atrial rate is too high; and if AV conduction is intact, the pacemaker does not pace the ventricle because the intrinsic conduction is too fast and the ventricular pace pulse is inhibited. However, when a pacemaker is in a single chamber ventricular (VVI, VVIR) or dual chamber non-tracking mode (DDI, DDIR), the pacemaker system can nonetheless perform an analogous operation to the dual chamber therapy described above, except that the pacemaker system controls ventricular pacing escape interval ($V-V_{esc}$) rather than AV_{esc} . In such an embodiment, $V-V_{esc}$ is initially shortened to correspond to a

relatively high ventricular rate when tracking is not available, and with time $V-V_{esc}$ is lengthened until fusion occurs. Thus, the algorithm is basically the same as for the above examples where AV_{esc} is modified, except control is through the $V-V$ escape interval.

Referring to Figure 7, there is shown a simplified flow diagram for carrying out single chamber mode pacing therapy for patients with cardiomyopathy. It is noted that the pacemaker system monitors the atrial rate each cycle, although this is not shown in the diagram of Fig. 7. At 702, it is determined whether the atrial rate is greater than a maximum rate, such that it is too high. If no, the system branches to synchronous operation. However, if the atrial rate is found to be too high, or some other arrhythmia is detected at 702, the routine goes to block 704 and sets $V-V_{esc}$ to a minimum value. Note that in a more sophisticated flow diagram the escape interval may be gradually ramped toward the minimum value, corresponding to a maximum asynchronous rate. At 706, the pacemaker waits for an event, and at 708 determines whether the event has been a timeout of a $V-V_{esc}$. If no, meaning that a natural ventricular depolarization was sensed, $V-V_{esc}$ is reset at 709; if the arrhythmia is continuing, the routine returns to wait at block 706. However, if there has been a timeout, a ventricular pace pulse is delivered at 712, and then at 714 the pacemaker system determines whether this has resulted in a fusion beat. If no, the routine branches through 718, where periodically $V-V_{esc}$ is incremented by $\Delta 1$. This increment can be done cyclically, or every N cycles, or by any other programmed arrangement. If fusion has been determined, at block 716 the pacemaker decrements $V-V_{esc}$ by subtracting $\Delta 2$. By this arrangement, the pacemaker varies the rate of the delivered asynchronous pulses so as to optimize pre-excitation in the same manner as discussed above for dual chamber-atrial tracking mode therapy. Following block 716 or 718, the routine checks to see if the arrhythmia is still present. If the pacemaker determines, at block 720, that the arrhythmia is over, then the program branches back to block 702.

It is noted that the embodiment of Figure 7 can be practiced with alternate techniques for determining when $V-V_{esc}$ should be adjusted. Thus, steps 714 and 716 can be eliminated, the routine periodically increasing $V-V_{esc}$ at 718 until a VS occurs, whereupon $V-V_{esc}$ is decremented to regain pacing. Thus, the scope of the Figure 7 embodiment is not limited to the preferred technique of detecting the occurrence of fusion in order to control the timing of delivered pace pulses.

What Is Claimed Is:

1. A dual chamber pacemaker, having atrial sense means for sensing atrial signals from a patient, ventricular sense means for sensing ventricular signals from a patient, ventricular pace means for generating and delivering ventricular pace pulses to said patient's right ventricle, and sync control means for controlling said pace means to generate and deliver a ventricular pace pulse at a controlled AV escape interval following a sensed atrial signal, said sync control means having AV_{esc} means for setting said AV escape interval, said AV_{esc} means comprising:

fusion means for detecting the occurrence of fusion beats, rate means for determining a rate of occurrence of fusion beats over a plurality of pacemaker cycles, and adjustment means for adjusting said AV escape interval as a function of said determined rate.

2. The pacemaker system as described in claim 1, said rate means having percentage means for determining the percentage of fusion beats over a plurality of pacemaker cycles, further comprising means for comparing said percentage to a predetermined minimum, and wherein said adjusting means adjusts said AV escape interval in response to a determination that said percentage is less than said predetermined minimum

3. The pacemaker system as described in claim 2, wherein said adjustment means decrements said AV interval by a predetermined amount in response to a determination that said percentage is greater than said predetermined minimum.

4. The pacemaker system as described in claim 3, comprising means for adjusting said predetermined amount as a function of said determined fusion percentage.

5. The pacemaker system as described in claim 3, comprising means for periodically incrementing said AV escape interval by a second predetermined amount which is less than said first predetermined amount.

6. The pacemaker system as described in claim 1, comprising programmer means for programming operation of said fusion means, said rate means and said adjustment means.

7. The pacemaker system as described in claim 1, wherein said fusion means and said adjustment means are continually operative.

8. The pacemaker system as described in claim 7, wherein said rate means comprises first rate means for detecting a first fusion occurrence rate over a first

predetermined number of pacemaker cycles, and second rate means for detecting a second fusion occurrence rate over a second predetermined number of pacemaker cycles.

9. The pacemaker system as described in claim 8, wherein said adjustment means has decrement means for decrementing said AV escape interval as a function of said first fusion occurrence rate, and increment means for incrementing said AV escape interval as a function of said second fusion occurrence rate.

10. A method of pacing therapy using a dual chamber pacemaker system, comprising

delivering a ventricular pace pulse upon the time out of an AV escape interval following an atrial event,

determining whenever a delivered ventricular pace pulse results in a fusion beat.

determining a measure of the rate of occurrence of fusion beats, and adjusting said AV escape interval as a function of said measure of rate of occurrence.

11. The method as described in claim 10, comprising determining a first percentage of fusion beats over a first predetermined interval.

12. The method as described in claim 11, comprising decrementing said AV escape interval by a first predetermined amount when said first percentage exceeds an allowed percentage.

13. The method as described in claim 11, comprising determining a second percentage of fusion beats over a second predetermined interval, and incrementing said AV escape interval by a second predetermined amount when said second percentage is less than a predetermined percentage.

14. A method of pacing therapy using a pacemaker in a non-tracking mode, comprising:

delivering ventricular pace pulses to a patient without a timed relationship to detected atrial events,

changing the V-V escape interval of delivered ventricular pace pulses, and determining when one or more said delivered ventricular pace pulses fail to result in full capture of the ventricle, and shortening said V-V escape interval in response to a determination of such a failure.

15. The method of pacing therapy as described in claim 14, comprising detecting the patient's rate of spontaneous atrial beats, detecting when the atrial rate is above a

predetermined atrial high rate limit, and initiating delivery of asynchronous ventricular pace pulses upon detecting an atrial rate above said high rate limit.

16. The method of pacing therapy as described in claim 15, comprising initially delivering asynchronous ventricular pace pulses at a predetermined ventricular high rate limit upon detecting an atrial rate above said atrial high rate limit.


17. The method of pacing therapy as described in claim 16, comprising limiting the duration of pacing at said ventricular high rate limit.

18. The method of pacing therapy as described in claim 14, comprising periodically increasing said V-V escape interval.

19. The method of pacing therapy as described in claim 14, comprising determining a fusion beat by comparing a characteristic of the QRS wave evoked by a ventricular pace pulse to a reference QRS wave characteristic.

20. The method of pacing therapy as described in claim 14, wherein said determining step comprises determining when a delivered pace pulse results in a fusion beat.

1 / 8



—
FIG.





FIG. 2

3/8






FIG. 4A

5/8




FIG. 4B

6/8




FIG. 6B




FIG. 5




FIG. 6A

8/8




FIG. 7

INTERNATIONAL SEARCH REPORT

International Application No
PCT 96/01091

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61N1/37 A61N1/368

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 597 728 (PACESETTER AB) 18 May 1994	1-3,6,7, 10
A	see column 17, line 5 - column 18, line 51; figure 4 ---	4,5
P,X	EP,A,0 681 850 (BIOTRONIK) 15 November 1995	1,10
P,A	see column 8, line 10 - line 53; claim 1 ---	2,9,13
P,A	US,A,5 391 189 (FRITS) 21 February 1995 see claims 1,19 ---	14
A	EP,A,0 600 631 (PACESETTER AB) 8 June 1994 see claim 14 ---	1,10
A	WO,A,92 04076 (VITATRON MEDICAL) 19 March 1992 see claims 7-11 ---	2-5
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

19 June 1996

Date of mailing of the international search report

15. 07. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+ 31-70) 340-3016

Authorized officer

Taccoen, J-F

INTERNATIONAL SEARCH REPORTInternational Application No
PCT/US 96/01091**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,95 32758 (MEDTRONIC) 7 December 1995 see claims 2,7 ---	14
A	US,A,5 103 820 (MARKOWITZ) 14 April 1992 see claim 5 ---	14
A	KENNETH McDONALD: "Permanent Pacing as treatment for hypertrophic cardiomyopathy" 1 July 1991 , THE AMERICAN JOURNAL OF CARDIOLOGY XP000569024 68 cited in the application see page 109 -----	1

INTERNATIONAL SEARCH REPORT

Information for patent family members

International Application No

PCT/96/01091

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0597728	18-05-94	US-A-	5340361	23-08-94
		AU-B-	661954	10-08-95
		AU-B-	5062993	26-05-94
		JP-A-	7016303	20-01-95
EP-A-0681850	15-11-95	DE-A-	4416779	16-11-95
US-A-5391189	21-02-95	EP-A-	0652029	10-05-95
EP-A-0600631	08-06-94	US-A-	5334220	02-08-94
		AU-B-	5070293	26-05-94
		JP-T-	8500272	16-01-96
		WO-A-	9411061	26-05-94
WO-A-9204076	19-03-92	US-A-	5144950	08-09-92
		AU-B-	647172	17-03-94
		AU-B-	8332691	30-03-92
		CA-A-	2088241	01-03-92
		DE-D-	69105738	19-01-95
		DE-T-	69105738	29-06-95
		EP-A-	0545967	16-06-93
		ES-T-	2065052	01-02-95
		JP-T-	6502554	24-03-94
WO-A-9532758	07-12-95	AU-B-	2358495	21-12-95
US-A-5103820	14-04-92	NONE		

THIS PAGE BLANK (USPTO)